Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Systemic and Intra-Nodal Activation of NK Cells After Rituximab Monotherapy for Follicular Lymphoma.

Enqvist M, Jacobs B, Junlén HR, Schaffer M, Melén CM, Friberg D, Wahlin BE, Malmberg KJ.

Front Immunol. 2019 Sep 12;10:2085. doi: 10.3389/fimmu.2019.02085. eCollection 2019.

2.

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor.

Sureda A, Chabannon C, Masszi T, Pohlreich D, Scheid C, Thieblemont C, Wahlin BE, Sakellari I, Russell N, Janikova A, Dabrowska-Iwanicka A, Touzeau C, Esquirol A, Jantunen E, van der Werf S, Bosman P, Boumendil A, Liu Q, Celanovic M, Montoto S, Dreger P.

Bone Marrow Transplant. 2019 Sep 30. doi: 10.1038/s41409-019-0693-z. [Epub ahead of print]

PMID:
31570781
3.

M7-FLIPI is not prognostic in follicular lymphoma patients with first-line rituximab chemo-free therapy.

Lockmer S, Ren W, Brodtkorb M, Østenstad B, Wahlin BE, Pan-Hammarström Q, Kimby E.

Br J Haematol. 2019 Aug 18. doi: 10.1111/bjh.16159. [Epub ahead of print]

PMID:
31423576
4.

Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application.

Mulder TA, Wahlin BE, Österborg A, Palma M.

Cancers (Basel). 2019 Jun 29;11(7). pii: E915. doi: 10.3390/cancers11070915. Review.

5.

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.

Zucca E, Rondeau S, Vanazzi A, Østenstad B, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJM, Lohri A, Novak U, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei SB, Ghielmini M, Kimby E; Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group.

Blood. 2019 Jul 25;134(4):353-362. doi: 10.1182/blood-2018-10-879643. Epub 2019 May 17.

PMID:
31101627
6.

The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994-2016.

Carlsten M, Jädersten M, Hellström A, Littmann K, Melén CM, Junlén HR, Sonnevi K, Ljungman P, Björkstrand B, Wahlin BE.

Exp Hematol Oncol. 2019 Mar 18;8:7. doi: 10.1186/s40164-019-0131-3. eCollection 2019.

7.

A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy.

Steen CB, Leich E, Myklebust JH, Lockmer S, Wise JF, Wahlin BE, Østenstad B, Liestøl K, Kimby E, Rosenwald A, Smeland EB, Holte H, Lingjærde OC, Brodtkorb M.

Haematologica. 2019 Oct;104(10):e460-e464. doi: 10.3324/haematol.2018.209080. Epub 2019 Mar 7. No abstract available.

8.

Expression of GNAZ, encoding the Gαz protein, predicts survival in mantle cell lymphoma.

Mundt F, Merrien M, Nygren L, Sutton LA, Christensson B, Wahlin BE, Rosenquist R, Sander B, Wasik AM.

Br J Haematol. 2019 May;185(4):708-712. doi: 10.1111/bjh.15810. Epub 2019 Feb 20.

PMID:
30788840
9.

Reply to M. Sorigue et al.

Lockmer S, Østenstad B, Hagberg H, Holte H, Wahlin BE, Wader KF, Smedby KE, Brown P, Kimby E.

J Clin Oncol. 2019 Mar 20;37(9):759-760. doi: 10.1200/JCO.18.02362. Epub 2019 Feb 8. No abstract available.

PMID:
30735430
10.

Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up.

Lockmer S, Østenstad B, Hagberg H, Holte H, Johansson AS, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenhølder M, Smedby KE, Brown P, Kimby E.

J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262. [Epub ahead of print]

PMID:
30285560
11.

Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study.

Wästerlid T, Biccler JL, Brown PN, Bøgsted M, Enblad G, Mészáros Jørgensen J, Christensen JH, Wahlin BE, Smedby KE, El-Galaly TC, Jerkeman M.

Ann Oncol. 2018 Aug 1;29(8):1882-1883. doi: 10.1093/annonc/mdy184. No abstract available.

PMID:
29790897
12.

Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma.

Ekberg S, Jerkeman M, Andersson PO, Enblad G, Wahlin BE, Hasselblom S, Andersson TM, Eloranta S, Smedby KE.

Am J Hematol. 2018 May 17. doi: 10.1002/ajh.25147. [Epub ahead of print]

13.

Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.

Björklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M, Cooley S, Miller JS, Klimkowska M, Schaffer M, Watz E, Wikström K, Blomberg P, Wahlin BE, Palma M, Hansson L, Ljungman P, Hellström-Lindberg E, Ljunggren HG, Malmberg KJ.

Clin Cancer Res. 2018 Apr 15;24(8):1834-1844. doi: 10.1158/1078-0432.CCR-17-3196. Epub 2018 Feb 14.

14.

Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry.

Molin D, Linderoth J, Wahlin BE.

Br J Haematol. 2017 May;177(3):449-456. doi: 10.1111/bjh.14567. Epub 2017 Feb 24.

PMID:
28233899
15.

G-CSF mobilized peripheral blood stem cell collection for allogeneic transplantation in healthy donors: Analysis of factors affecting yield.

Machaczka M, Hägglund H, Staver E, Joks M, Hassan M, Wahlin BE, Axdorph Nygell U.

J Clin Apher. 2017 Dec;32(6):384-391. doi: 10.1002/jca.21524. Epub 2017 Jan 19.

PMID:
28101890
16.

Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.

Melén CM, Enblad G, Sonnevi K, Junlén HR, Smedby KE, Jerkeman M, Wahlin BE.

Br J Haematol. 2016 Nov;175(4):614-622. doi: 10.1111/bjh.14399. Epub 2016 Oct 28.

PMID:
27790699
17.

The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.

Blaker YN, Spetalen S, Brodtkorb M, Lingjaerde OC, Beiske K, Østenstad B, Sander B, Wahlin BE, Melen CM, Myklebust JH, Holte H, Delabie J, Smeland EB.

Br J Haematol. 2016 Oct;175(1):102-14. doi: 10.1111/bjh.14201. Epub 2016 Jun 24.

PMID:
27341313
18.

Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.

Kimby E, Östenstad B, Brown P, Hagberg H, Erlanson M, Holte H, Linden O, Johansson AS, Ahlgren T, Wader K, Wahlin BE, Delabie J, Sundström C; Nordic Lymphoma Group (NLG).

Leuk Lymphoma. 2015;56(9):2598-607. doi: 10.3109/10428194.2015.1014363. Epub 2015 Mar 11.

PMID:
25686644
19.

Fecal calprotectin as a biomarker of intestinal graft versus host disease after allogeneic hematopoietic stem cell transplantation.

Lorenz F, Marklund S, Werner M, Palmqvist R, Wahlin BE, Wahlin A.

Sci Rep. 2015 Jan 21;5:7920. doi: 10.1038/srep07920.

20.

Perturbations of the endocannabinoid system in mantle cell lymphoma: correlations to clinical and pathological features.

Wasik AM, Nygren L, Almestrand S, Zong F, Flygare J, Wennerholm SB, Saft L, Andersson P, Kimby E, Wahlin BE, Christensson B, Sander B.

Oncoscience. 2014 Sep 4;1(8):550-7. eCollection 2014.

21.

T-cell levels are prognostic in mantle cell lymphoma.

Nygren L, Wasik AM, Baumgartner-Wennerholm S, Jeppsson-Ahlberg Å, Klimkowska M, Andersson P, Buhrkuhl D, Christensson B, Kimby E, Wahlin BE, Sander B.

Clin Cancer Res. 2014 Dec 1;20(23):6096-104. doi: 10.1158/1078-0432.CCR-14-0889. Epub 2014 Oct 7.

22.

Clinical utility of different bone marrow examination methods in the diagnosis of adults with sporadic Gaucher disease type 1.

Machaczka M, Markuszewska-Kuczyńska A, Regenthal S, Jurczyszyn A, Gałązka K, Wahlin BE, Klimkowska M.

Pol Arch Med Wewn. 2014;124(11):587-92. Epub 2014 Sep 3.

23.

Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study.

Junlén HR, Peterson S, Kimby E, Lockmer S, Lindén O, Nilsson-Ehle H, Erlanson M, Hagberg H, Rådlund A, Hagberg O, Wahlin BE.

Leukemia. 2015 Mar;29(3):668-76. doi: 10.1038/leu.2014.251. Epub 2014 Aug 25.

PMID:
25151959
24.

The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium.

Sander B, de Jong D, Rosenwald A, Xie W, Balagué O, Calaminici M, Carreras J, Gaulard P, Gribben J, Hagenbeek A, Kersten MJ, Molina TJ, Lee A, Montes-Moreno S, Ott G, Raemaekers J, Salles G, Sehn L, Thorns C, Wahlin BE, Gascoyne RD, Weller E.

Haematologica. 2014 Apr;99(4):715-25. doi: 10.3324/haematol.2013.095257. Epub 2014 Feb 7.

25.

High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse.

Machaczka M, Johansson JE, Remberger M, Hallböök H, Lazarevic VLj, Wahlin BE, Omar H, Wahlin A, Juliusson G, Kimby E, Hägglund H.

Med Oncol. 2013 Dec;30(4):762. doi: 10.1007/s12032-013-0762-x. Epub 2013 Nov 9.

PMID:
24214180
26.

Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy.

Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg Å, Hjalmarsson E, Holte H, Østenstad B, Brown PD, Smeland EB, Kimby E.

Leuk Lymphoma. 2014 Feb;55(2):288-95. doi: 10.3109/10428194.2013.802778. Epub 2013 Jun 14.

PMID:
23662992
27.

Entourage: the immune microenvironment following follicular lymphoma.

Wahlin BE, Sander B, Christensson B, Ostenstad B, Holte H, Brown PD, Sundström C, Kimby E.

Blood Cancer J. 2012 Jan;2(1):e52. doi: 10.1038/bcj.2011.53. Epub 2012 Jan 20.

28.

Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times.

Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB, Sundström C, Christensson B, Sander B.

Br J Haematol. 2012 Jan;156(2):225-33. doi: 10.1111/j.1365-2141.2011.08942.x. Epub 2011 Nov 30.

PMID:
22126847
29.

Association between P-glycoprotein and lymphoid antigen expression on myeloblasts versus therapy response and survival in de novo acute myeloid leukemia: long-term follow-up results.

Machaczka M, Wahlin BE, Piatkowska-Jakubas B, Rucinska M, Jurczak W, Balana-Nowak A, Klimkowska M, Hägglund H, Skotnicki AB.

Med Oncol. 2012 Sep;29(3):2070-6. doi: 10.1007/s12032-011-0044-4. Epub 2011 Aug 23.

PMID:
21861206
30.

Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery.

Ungerstedt JS, Watz E, Uttervall K, Johansson BM, Wahlin BE, Näsman P, Ljungman P, Gruber A, Axdorph Nygell U, Nahi H.

Med Oncol. 2012 Sep;29(3):2191-9. doi: 10.1007/s12032-011-0029-3. Epub 2011 Jul 22.

PMID:
21779930
31.

T cells in tumors and blood predict outcome in follicular lymphoma treated with rituximab.

Wahlin BE, Sundström C, Holte H, Hagberg H, Erlanson M, Nilsson-Ehle H, Lindén O, Nordström M, Ostenstad B, Geisler CH, Brown Pde N, Lehtinen T, Maisenhölder M, Tierens AM, Sander B, Christensson B, Kimby E.

Clin Cancer Res. 2011 Jun 15;17(12):4136-44. doi: 10.1158/1078-0432.CCR-11-0264. Epub 2011 Apr 25.

32.

Hyperferritinemia is associated with low incidence of graft versus host disease, high relapse rate, and impaired survival in patients with blood disorders receiving allogeneic hematopoietic stem cell grafts.

Wahlin A, Lorenz F, Fredriksson M, Remberger M, Wahlin BE, Hägglund H.

Med Oncol. 2011 Jun;28(2):552-8. doi: 10.1007/s12032-010-9496-1.

PMID:
20393815
33.

A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1--positive, regulatory, cytotoxic, and helper T cells and macrophages.

Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, Christensson B, Sander B, Kimby E.

Clin Cancer Res. 2010 Jan 15;16(2):637-50. doi: 10.1158/1078-0432.CCR-09-2487. Epub 2010 Jan 12.

34.

CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.

Wahlin BE, Sander B, Christensson B, Kimby E.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):388-97.

Supplemental Content

Loading ...
Support Center